Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 9/20 | 0.73 |
| ▸ | TGM2 | P21980 | 1/20 | 0.73 |
| ▸ | NT5E | P21589 | 1/20 | 0.69 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.65 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.65 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.65 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.64 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.62 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167315 | 0.92 | TGM2 (0.75) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL18769114 | 0.92 | TGM2 (0.85) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL21067722 | 0.92 | TGM2 (0.85) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL29429843 | 0.92 | TGM2 (0.85) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL851357 | 0.92 | TGM2 (0.85) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL21742685 | 0.91 | TGM2 (0.72) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL21742686 | 0.91 | TGM2 (0.72) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL21742884 | 0.91 | TGM2 (0.73) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL21742885 | 0.91 | TGM2 (0.73) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL21742887 | 0.90 | TGM2 (0.75) | KRASTGM2NT5EFUT5P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484907-B1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | UNIV WARSZAWSKI (PL) | 2020-05-13 | — | — | EP | disclosed |
| US-20200055891-A1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055891-A1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | RNGTT, RNMT, NSUN3 | KRAS 3403/4885TGM2 3588/4885NT5E 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.